ClinicalTrials.gg
CompletedNCT01111331Updated Jul 23, 2014Results posted

Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers

A Phase 1 interventional study of BI 10773 25 mg and Warfarin 25 mg in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-23.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The objective of the current study is to investigate the bioavailability of BI 10773 and of warfarin after concomitant multiple oral administration of BI 10773 and a single oral dose of warfarin in comparison to BI 10773 and warfarin given alone, and to investigate the pharmacodynamics of a single oral dose of warfarin with and without concomitant multiple oral administration of BI 10773.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria:

Healthy male subjects

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    BI 10773 25 mg

    1 tablet 25 mg BI 10773 qd for 5 days

    Drug: BI 10773 25 mg

  • Experimental
    BI 10773 25 mg + Warfarin 25 mg

    1 tablet 25 mg BI 10773 qd for 7 days plus 5 tablets 5 mg warfarin single dose

    Drug: BI 10773 25 mg · Drug: Warfarin 25 mg

  • Active comparator
    Warfarin 25 mg

    5 tablets 5 mg warfarin single dose

    Drug: Warfarin

Interventions

06

What researchers measure

Primary outcomes

  1. Empagliflozin: Area Under the Curve for the Dosing Interval at Steady State (AUCτ,ss)

    Area under the plasma concentration-time curve for the dosing interval τ at steady state In addition to the specified time frame, pre-dose samples were collected on Days 1, 3, and 4 for empa and a post-dose sample on day 1 for empa plus warfarin.

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h post-dose on Day 5 for for empa; 0h, 20min, 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h for empa plus warfarin.

  2. Empagliflozin: Maximum Measured Concentration at Steady State(Cmax,ss)

    Maximum measured plasma concentration of empagliflozin (empa) for the dosing interval τ at steady state. In addition to the below time frame, pre-dose samples were collected on Days 1, 3, and 4 for empa and a post-dose sample on day 1 for empa plus warfarin.

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h post-dose on Day 5 for for empa; 0h, 20min, 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h for empa plus warfarin.

  3. Warfarin R-enantiomers: Area Under the Curve 0 to Infinity (AUC0-∞)

    Area under the plasma concentration-time curve from time of dosing extrapolated to infinity.

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  4. Warfarin R-enantiomers: Maximum Measured Concentration (Cmax)

    Maximum measured concentration of the analyte in plasma.

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  5. Warfarin S-enantiomers: Area Under the Curve 0 to Infinity (AUC0-∞)

    Area under the plasma concentration-time curve from time of dosing extrapolated to infinity.

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  6. Warfarin S-enantiomers: Maximum Measured Concentration (Cmax)

    Maximum measured concentration of the analyte in plasma

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

Secondary outcomes

  1. Empagliflozin: Plasma Concentration 24 Hours After Administration of Dose (C24,N)

    Plasma concentration of empagliflozin (empa) measured 24 hours after administration of the fourth dose (Cpre,5) and after the sixth dose (Cpre,7).

    Time frame: 24 hours after dose 4 or 6 respectively (day 5 and day 7)

  2. Empagliflozin: Terminal Rate Constant at Steady State (λz,ss)

    Terminal rate constant of empagliflozin (empa) in plasma at steady state. In addition to the below time frame, pre-dose samples were collected on Days 1, 3, and 4 for empa and a post-dose sample on day 1 for empa plus warfarin.

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h post-dose on Day 5 for for empa; 0h, 20min, 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h for empa plus warfarin.

  3. Empagliflozin: Terminal Half-life at Steady State (t1/2,ss)

    Terminal half-life of empagliflozin (empa) in plasma at steady state. In addition to the below time frame, pre-dose samples were collected on Days 1, 3, and 4 for empa and a post-dose sample on day 1 for empa plus warfarin.

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h post-dose on Day 5 for for empa; 0h, 20min, 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h for empa plus warfarin.

  4. Empagliflozin: Time to Maximum Plasma Concentration at Steady State (Tmax,ss)

    Time from last dosing to maximum plasma concentration at steady state over a uniform dosing interval τ. In addition to the below time frame, pre-dose samples were collected on Days 1, 3, and 4 for empa and a post-dose sample on day 1 for empa plus warfarin.

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h post-dose on Day 5 for for empa; 0h, 20min, 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h for empa plus warfarin

  5. Empagliflozin: Mean Residence Time at Steady State After Oral Administration (MRTpo,ss)

    Mean residence time of empagliflozin (empa) in the body at steady state after oral administration. In addition to the below time frame, pre-dose samples were collected on Days 1, 3, and 4 for empa and a post-dose sample on day 1 for empa plus warfarin.

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h post-dose on Day 5 for for empa; 0h, 20min, 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h for empa plus warfarin.

  6. Empagliflozin: Apparent Clearance at Steady State (CL/F,ss)

    Apparent clearance in plasma after extravascular administration at steady state. In addition to the below time frame, pre-dose samples were collected on Days 1, 3, and 4 for empa and a post-dose sample on day 1 for empa plus warfarin.

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h post-dose on Day 5 for for empa; 0h, 20min, 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h for empa plus warfarin.

  7. Empagliflozin: Apparent Volume of Distribution Following Extravascular Administration (Vz/F,ss)

    Apparent volume of distribution during the terminal phase at steady state following extravascular administration. In addition to the below time frame, pre-dose samples were collected on Days 1, 3, and 4 for empa and a post-dose sample on day 1 for empa plus warfarin.

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h post-dose on Day 5 for for empa; 0h, 20min, 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h for empa plus warfarin

  8. Warfarin R-enantiomers: Area Under the Curve 0 to Last Measurable Data Point (AUC0-tz)

    Area under the plasma concentration-time curve from time of dosing to time of last measurable data point.

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  9. Warfarin R-enantiomers: Time to Maximum Plasma Concentration (Tmax)

    Time from dosing until maximum plasma concentration is reached

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  10. Warfarin R-enantiomers: Terminal Rate Constant (λz)

    Terminal rate constant in plasma

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  11. Warfarin R-enantiomers: Terminal Half-life (t1/2)

    Terminal half-life of the analyte in plasma

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  12. Warfarin R-enantiomers: Mean Residence Time After Oral Administration (MRTpo)

    Mean residence time of the analyte in the body after oral administration

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  13. Warfarin R-enantiomers: Apparent Clearance After Extravascular Administration (CL/F)

    Apparent clearance in plasma after extravascular administration

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  14. Warfarin R-enantiomers: Apparent Volume of Distribution Following Extravascular Administration (Vz/F)

    Apparent volume of distribution during the terminal phase λz following extravascular administration

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  15. Warfarin S-enantiomers: Area Under the Curve 0 to Last Measurable Data Point (AUC0-tz)

    Area under the plasma concentration-time curve from time of dosing to time of last measurable data point.

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  16. Warfarin S-enantiomers: Time to Maximum Plasma Concentration (Tmax)

    Time from dosing until maximum plasma concentration is reached

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  17. Warfarin S-enantiomers: Terminal Rate Constant (λz)

    Terminal rate constant in plasma

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  18. Warfarin S-enantiomers: Terminal Half-life (t1/2)

    Terminal half-life of the analyte in plasma

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  19. Warfarin S-enantiomers: Mean Residence Time After Oral Administration (MRTpo)

    Mean residence time of the analyte in the body after oral administration

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  20. Warfarin S-enantiomers: Apparent Clearance After Extravascular Administration (CL/F)

    Apparent clearance in plasma after extravascular administration

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  21. Warfarin S-enantiomers: Apparent Volume of Distribution Following Extravascular Administration (Vz/F)

    Apparent volume of distribution during the terminal phase λz following extravascular administration

    Time frame: 0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  22. Warfarin: Peak International Normalised Ratio (INRmax)

    Peak international normalised ratio for warfarin, measured as the maximum INR over time.

    Time frame: 0 hours (h), 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  23. Warfarin: Area Under the INR-time Curve From 0 to Last Measurable Data Point (INR AUEC0-tz)

    Area under the concentration time curve of the INR measurements over the time interval from 0 to the time of the last quantifiable data point.

    Time frame: 0 hours (h), 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  24. Warfarin: Peak International Normalised Ratio Adjusted to Baseline (INRmax,Base)

    Peak international normalised ratio for warfarin adjusted for baseline value (before any trial drug administration) of peak international normalised ratio

    Time frame: 0 hours (h), 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  25. Warfarin: Peak Prothrombin Time (PTmax)

    Peak prothrombin time

    Time frame: 0 hours (h), 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  26. Warfarin: Area Under the INR-time Curve From 0 to Last Measurable Data Point Adjusted to Baseline (INR AUEC0-tz,Base)

    Area under the INR-time curve from time of dosing to time of last measurable data point adjusted for baseline value (before any trial drug administration) of area under the INR-time curve

    Time frame: 0 hours (h), 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  27. Warfarin: Area Under the PT-time Curve From 0 to Last Measurable Data Point (PT AUEC0-tz)

    Area under the PT-time curve from time of dosing to time of last measurable data point

    Time frame: 0 hours (h), 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  28. Warfarin: Peak Prothrombin Time Adjusted to Baseline (PTmax,Base)

    Peak prothrombin time adjusted for baseline value (before any trial drug administration) of peak prothrombin

    Time frame: 0 hours (h), 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  29. Warfarin: Area Under the PT-time Curve From 0 to Last Measurable Data Point Adjusted to Baseline (PT AUEC0-tz,Base)

    Area under the PT-time curve from time of dosing to time of last measurable data point adjusted for baseline value (before any trial drug administration) of area under the PT-time curve

    Time frame: 0 hours (h), 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin

  30. Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by Investigator

    Clinically relevant abnormalities for physical examination, vital signs, ECG, blood chemistry and assessment of tolerability by investigator. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.

    Time frame: Drug administration until beginning of next sequence/end of trial, 35 days

07

Results

Posted Jul 23, 2014

Participant flow

Participant flow — Overall Study
MilestoneEmpa / Empa Plus Warfarin / WarfarinWarfarin / Empa / Empa Plus Warfarin
Started99
Completed99
Not completed00

Outcome measures

PrimaryEmpagliflozin: Area Under the Curve for the Dosing Interval at Steady State (AUCτ,ss)

Area under the plasma concentration-time curve for the dosing interval τ at steady state In addition to the specified time frame, pre-dose samples were collected on Days 1, 3, and 4 for empa and a post-dose sample on day 1 for empa plus warfarin.

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h post-dose on Day 5 for for empa; 0h, 20min, 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h for empa plus warfarin.
Reported as:
Geometric mean · nmol*h/L
Empagliflozin: Area Under the Curve for the Dosing Interval at Steady State (AUCτ,ss)
nmol*h/LEmpaEmpa Plus Warfarin
Empagliflozin: Area Under the Curve for the Dosing Interval at Steady State (AUCτ,ss)4580.38 ± 7.04621.37 ± 7.0
Statistical analysis
  • Empa vs Empa Plus Warfarin · ANOVA · Geometric mean ratio: 100.89 · 90% CI 96.86 to 105.10Standard deviation is actually the intra-individual geometric coefficient of variation (gCV)
PrimaryEmpagliflozin: Maximum Measured Concentration at Steady State(Cmax,ss)

Maximum measured plasma concentration of empagliflozin (empa) for the dosing interval τ at steady state. In addition to the below time frame, pre-dose samples were collected on Days 1, 3, and 4 for empa and a post-dose sample on day 1 for empa plus warfarin.

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h post-dose on Day 5 for for empa; 0h, 20min, 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h for empa plus warfarin.
Reported as:
Geometric mean · nmol/L
Empagliflozin: Maximum Measured Concentration at Steady State(Cmax,ss)
nmol/LEmpaEmpa Plus Warfarin
Empagliflozin: Maximum Measured Concentration at Steady State(Cmax,ss)759.96 ± 19.9764.82 ± 19.9
Statistical analysis
  • Empa vs Empa Plus Warfarin · ANOVA · p = 0.0021 (p-value for geometric mean ratio being outside interval 80% to 125%) · Geometric mean ratio: 100.64 · 90% CI 89.79 to 112.80Standard deviation is actually the intra-individual gCV
PrimaryWarfarin R-enantiomers: Area Under the Curve 0 to Infinity (AUC0-∞)

Area under the plasma concentration-time curve from time of dosing extrapolated to infinity.

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · ng*h/mL
Warfarin R-enantiomers: Area Under the Curve 0 to Infinity (AUC0-∞)
ng*h/mLWarfarinEmpa Plus Warfarin
Warfarin R-enantiomers: Area Under the Curve 0 to Infinity (AUC0-∞)63585.71 ± 5.762626.35 ± 5.7
Statistical analysis
  • Warfarin vs Empa Plus Warfarin · ANOVA · Geometric mean ratio: 98.49 · 90% CI 95.29 to 101.80Standard deviation is actually the geometric coefficient of variation (gCV)
PrimaryWarfarin R-enantiomers: Maximum Measured Concentration (Cmax)

Maximum measured concentration of the analyte in plasma.

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · ng/mL
Warfarin R-enantiomers: Maximum Measured Concentration (Cmax)
ng/mLWarfarinEmpa Plus Warfarin
Warfarin R-enantiomers: Maximum Measured Concentration (Cmax)1404.07 ± 12.41374.40 ± 12.4
Statistical analysis
  • Warfarin vs Empa Plus Warfarin · ANOVA · p = 0.0001 · Geometric mean ratio: 97.89 · 90% CI 91.12 to 105.15Standard deviation is actually the geometric coefficient of variation (gCV)
PrimaryWarfarin S-enantiomers: Area Under the Curve 0 to Infinity (AUC0-∞)

Area under the plasma concentration-time curve from time of dosing extrapolated to infinity.

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · ng*h/mL
Warfarin S-enantiomers: Area Under the Curve 0 to Infinity (AUC0-∞)
ng*h/mLWarfarinEmpa Plus Warfarin
Warfarin S-enantiomers: Area Under the Curve 0 to Infinity (AUC0-∞)37493.28 ± 4.535949.84 ± 4.5
Statistical analysis
  • Warfarin vs Empa Plus Warfarin · ANOVA · Geometric mean ratio: 95.88 · 90% CI 93.40 to 98.43Standard deviation is actually the intra-individual gCV
PrimaryWarfarin S-enantiomers: Maximum Measured Concentration (Cmax)

Maximum measured concentration of the analyte in plasma

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · ng/mL
Warfarin S-enantiomers: Maximum Measured Concentration (Cmax)
ng/mLWarfarinEmpa Plus Warfarin
Warfarin S-enantiomers: Maximum Measured Concentration (Cmax)1441.66 ± 12.71425.56 ± 12.7
Statistical analysis
  • Warfarin vs Empa Plus Warfarin · ANOVA · p = 0.0001 (p-value for geometric mean ratio being outside interval 80% to 125%) · Geometric mean ratio: 98.88 · 90% CI 91.84 to 106.47Standard deviation is actually the intra-individual gCV
SecondaryEmpagliflozin: Plasma Concentration 24 Hours After Administration of Dose (C24,N)

Plasma concentration of empagliflozin (empa) measured 24 hours after administration of the fourth dose (Cpre,5) and after the sixth dose (Cpre,7).

Time frame:
24 hours after dose 4 or 6 respectively (day 5 and day 7)
Reported as:
Geometric mean · nmol/L
Empagliflozin: Plasma Concentration 24 Hours After Administration of Dose (C24,N)
nmol/LEmpaEmpa Plus Warfarin
Cpre,540.8 ± 33.4NA ± NA
Cpre,7NA ± NA41.6 ± 36.7
SecondaryEmpagliflozin: Terminal Rate Constant at Steady State (λz,ss)

Terminal rate constant of empagliflozin (empa) in plasma at steady state. In addition to the below time frame, pre-dose samples were collected on Days 1, 3, and 4 for empa and a post-dose sample on day 1 for empa plus warfarin.

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h post-dose on Day 5 for for empa; 0h, 20min, 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h for empa plus warfarin.
Reported as:
Geometric mean · 1/h
Empagliflozin: Terminal Rate Constant at Steady State (λz,ss)
1/hEmpaEmpa Plus Warfarin
Empagliflozin: Terminal Rate Constant at Steady State (λz,ss)0.10 ± 10.60.10 ± 11.7
SecondaryEmpagliflozin: Terminal Half-life at Steady State (t1/2,ss)

Terminal half-life of empagliflozin (empa) in plasma at steady state. In addition to the below time frame, pre-dose samples were collected on Days 1, 3, and 4 for empa and a post-dose sample on day 1 for empa plus warfarin.

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h post-dose on Day 5 for for empa; 0h, 20min, 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h for empa plus warfarin.
Reported as:
Geometric mean · h
Empagliflozin: Terminal Half-life at Steady State (t1/2,ss)
hEmpaEmpa Plus Warfarin
Empagliflozin: Terminal Half-life at Steady State (t1/2,ss)6.67 ± 10.67.07 ± 11.7
SecondaryEmpagliflozin: Time to Maximum Plasma Concentration at Steady State (Tmax,ss)

Time from last dosing to maximum plasma concentration at steady state over a uniform dosing interval τ. In addition to the below time frame, pre-dose samples were collected on Days 1, 3, and 4 for empa and a post-dose sample on day 1 for empa plus warfarin.

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h post-dose on Day 5 for for empa; 0h, 20min, 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h for empa plus warfarin
Reported as:
Median · h
Empagliflozin: Time to Maximum Plasma Concentration at Steady State (Tmax,ss)
hEmpaEmpa Plus Warfarin
Empagliflozin: Time to Maximum Plasma Concentration at Steady State (Tmax,ss)1.50 ± 35.01.00 ± 55.5
SecondaryEmpagliflozin: Mean Residence Time at Steady State After Oral Administration (MRTpo,ss)

Mean residence time of empagliflozin (empa) in the body at steady state after oral administration. In addition to the below time frame, pre-dose samples were collected on Days 1, 3, and 4 for empa and a post-dose sample on day 1 for empa plus warfarin.

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h post-dose on Day 5 for for empa; 0h, 20min, 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h for empa plus warfarin.
Reported as:
Geometric mean · h
Empagliflozin: Mean Residence Time at Steady State After Oral Administration (MRTpo,ss)
hEmpaEmpa Plus Warfarin
Empagliflozin: Mean Residence Time at Steady State After Oral Administration (MRTpo,ss)8.64 ± 12.69.08 ± 17.5
SecondaryEmpagliflozin: Apparent Clearance at Steady State (CL/F,ss)

Apparent clearance in plasma after extravascular administration at steady state. In addition to the below time frame, pre-dose samples were collected on Days 1, 3, and 4 for empa and a post-dose sample on day 1 for empa plus warfarin.

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h post-dose on Day 5 for for empa; 0h, 20min, 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h for empa plus warfarin.
Reported as:
Geometric mean · mL/min
Empagliflozin: Apparent Clearance at Steady State (CL/F,ss)
mL/minEmpaEmpa Plus Warfarin
Empagliflozin: Apparent Clearance at Steady State (CL/F,ss)187 ± 14.8183 ± 16.9
SecondaryEmpagliflozin: Apparent Volume of Distribution Following Extravascular Administration (Vz/F,ss)

Apparent volume of distribution during the terminal phase at steady state following extravascular administration. In addition to the below time frame, pre-dose samples were collected on Days 1, 3, and 4 for empa and a post-dose sample on day 1 for empa plus warfarin.

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h post-dose on Day 5 for for empa; 0h, 20min, 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h for empa plus warfarin
Reported as:
Geometric mean · L
Empagliflozin: Apparent Volume of Distribution Following Extravascular Administration (Vz/F,ss)
LEmpaEmpa Plus Warfarin
Empagliflozin: Apparent Volume of Distribution Following Extravascular Administration (Vz/F,ss)108 ± 8.63112 ± 12.7
SecondaryWarfarin R-enantiomers: Area Under the Curve 0 to Last Measurable Data Point (AUC0-tz)

Area under the plasma concentration-time curve from time of dosing to time of last measurable data point.

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · ng*h/mL
Warfarin R-enantiomers: Area Under the Curve 0 to Last Measurable Data Point (AUC0-tz)
ng*h/mLWarfarinEmpa Plus Warfarin
Warfarin R-enantiomers: Area Under the Curve 0 to Last Measurable Data Point (AUC0-tz)58556.93 ± 5.357911.05 ± 5.3
Statistical analysis
  • Warfarin vs Empa Plus Warfarin · ANOVA · Geometric mean ratio: 98.90 · 90% CI 95.89 to 102.00Standard deviation is actually the geometric coefficient of variation (gCV)
SecondaryWarfarin R-enantiomers: Time to Maximum Plasma Concentration (Tmax)

Time from dosing until maximum plasma concentration is reached

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Median · h
Warfarin R-enantiomers: Time to Maximum Plasma Concentration (Tmax)
hWarfarinEmpa Plus Warfarin
Warfarin R-enantiomers: Time to Maximum Plasma Concentration (Tmax)0.84 ± 79.51.00 ± 98.7
SecondaryWarfarin R-enantiomers: Terminal Rate Constant (λz)

Terminal rate constant in plasma

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · 1/h
Warfarin R-enantiomers: Terminal Rate Constant (λz)
1/hWarfarinEmpa Plus Warfarin
Warfarin R-enantiomers: Terminal Rate Constant (λz)0.0147 ± 12.10.0151 ± 15.4
SecondaryWarfarin R-enantiomers: Terminal Half-life (t1/2)

Terminal half-life of the analyte in plasma

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · h
Warfarin R-enantiomers: Terminal Half-life (t1/2)
hWarfarinEmpa Plus Warfarin
Warfarin R-enantiomers: Terminal Half-life (t1/2)47.1 ± 12.145.8 ± 15.4
SecondaryWarfarin R-enantiomers: Mean Residence Time After Oral Administration (MRTpo)

Mean residence time of the analyte in the body after oral administration

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · h
Warfarin R-enantiomers: Mean Residence Time After Oral Administration (MRTpo)
hWarfarinEmpa Plus Warfarin
Warfarin R-enantiomers: Mean Residence Time After Oral Administration (MRTpo)62.9 ± 16.061.2 ± 19.1
SecondaryWarfarin R-enantiomers: Apparent Clearance After Extravascular Administration (CL/F)

Apparent clearance in plasma after extravascular administration

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · mL/min
Warfarin R-enantiomers: Apparent Clearance After Extravascular Administration (CL/F)
mL/minWarfarinEmpa Plus Warfarin
Warfarin R-enantiomers: Apparent Clearance After Extravascular Administration (CL/F)6.55 ± 20.86.65 ± 24.2
SecondaryWarfarin R-enantiomers: Apparent Volume of Distribution Following Extravascular Administration (Vz/F)

Apparent volume of distribution during the terminal phase λz following extravascular administration

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · L
Warfarin R-enantiomers: Apparent Volume of Distribution Following Extravascular Administration (Vz/F)
LWarfarinEmpa Plus Warfarin
Warfarin R-enantiomers: Apparent Volume of Distribution Following Extravascular Administration (Vz/F)26.7 ± 15.526.4 ± 13.6
SecondaryWarfarin S-enantiomers: Area Under the Curve 0 to Last Measurable Data Point (AUC0-tz)

Area under the plasma concentration-time curve from time of dosing to time of last measurable data point.

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · ng*h/mL
Warfarin S-enantiomers: Area Under the Curve 0 to Last Measurable Data Point (AUC0-tz)
ng*h/mLWarfarinEmpa Plus Warfarin
Warfarin S-enantiomers: Area Under the Curve 0 to Last Measurable Data Point (AUC0-tz)36386.49 ± 4.434962.95 ± 4.4
Statistical analysis
  • Warfarin vs Empa Plus Warfarin · ANOVA · Geometric mean ratio: 96.09 · 90% CI 93.64 to 98.60Standard deviation is actually the intra-individual gCV
SecondaryWarfarin S-enantiomers: Time to Maximum Plasma Concentration (Tmax)

Time from dosing until maximum plasma concentration is reached

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Median · h
Warfarin S-enantiomers: Time to Maximum Plasma Concentration (Tmax)
hWarfarinEmpa Plus Warfarin
Warfarin S-enantiomers: Time to Maximum Plasma Concentration (Tmax)0.68 ± 74.60.84 ± 85.6
SecondaryWarfarin S-enantiomers: Terminal Rate Constant (λz)

Terminal rate constant in plasma

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · 1/h
Warfarin S-enantiomers: Terminal Rate Constant (λz)
1/hWarfarinEmpa Plus Warfarin
Warfarin S-enantiomers: Terminal Rate Constant (λz)0.0187 ± 13.70.0189 ± 12.4
SecondaryWarfarin S-enantiomers: Terminal Half-life (t1/2)

Terminal half-life of the analyte in plasma

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · h
Warfarin S-enantiomers: Terminal Half-life (t1/2)
hWarfarinEmpa Plus Warfarin
Warfarin S-enantiomers: Terminal Half-life (t1/2)37.0 ± 13.736.7 ± 12.4
SecondaryWarfarin S-enantiomers: Mean Residence Time After Oral Administration (MRTpo)

Mean residence time of the analyte in the body after oral administration

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · h
Warfarin S-enantiomers: Mean Residence Time After Oral Administration (MRTpo)
hWarfarinEmpa Plus Warfarin
Warfarin S-enantiomers: Mean Residence Time After Oral Administration (MRTpo)40.8 ± 13.838.9 ± 15.0
SecondaryWarfarin S-enantiomers: Apparent Clearance After Extravascular Administration (CL/F)

Apparent clearance in plasma after extravascular administration

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · mL/min
Warfarin S-enantiomers: Apparent Clearance After Extravascular Administration (CL/F)
mL/minWarfarinEmpa Plus Warfarin
Warfarin S-enantiomers: Apparent Clearance After Extravascular Administration (CL/F)11.1 ± 17.811.6 ± 16.1
SecondaryWarfarin S-enantiomers: Apparent Volume of Distribution Following Extravascular Administration (Vz/F)

Apparent volume of distribution during the terminal phase λz following extravascular administration

Time frame:
0 hours (h), 20 minutes (min), 40min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · L
Warfarin S-enantiomers: Apparent Volume of Distribution Following Extravascular Administration (Vz/F)
LWarfarinEmpa Plus Warfarin
Warfarin S-enantiomers: Apparent Volume of Distribution Following Extravascular Administration (Vz/F)35.6 ± 21.136.8 ± 12.7
SecondaryWarfarin: Peak International Normalised Ratio (INRmax)

Peak international normalised ratio for warfarin, measured as the maximum INR over time.

Time frame:
0 hours (h), 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · Ratio
Warfarin: Peak International Normalised Ratio (INRmax)
RatioWarfarinEmpa Plus Warfarin
Warfarin: Peak International Normalised Ratio (INRmax)1.76 ± NA1.53 ± 23.68
Statistical analysis
  • Warfarin vs Empa Plus Warfarin · ANOVA · Geometric mean ratio: 0.87 · 95% CI 0.73 to 1.04Based on ANOVA with terms for sequence, subjects within sequence, period, treatment and the baseline INR value
SecondaryWarfarin: Area Under the INR-time Curve From 0 to Last Measurable Data Point (INR AUEC0-tz)

Area under the concentration time curve of the INR measurements over the time interval from 0 to the time of the last quantifiable data point.

Time frame:
0 hours (h), 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · ratio*h
Warfarin: Area Under the INR-time Curve From 0 to Last Measurable Data Point (INR AUEC0-tz)
ratio*hWarfarinEmpa Plus Warfarin
Warfarin: Area Under the INR-time Curve From 0 to Last Measurable Data Point (INR AUEC0-tz)202.54 ± NA178.08 ± 10.75
Statistical analysis
  • Warfarin vs Empa Plus Warfarin · ANOVA · Geometric mean ratio: 0.88 · 95% CI 0.79 to 0.98Based on ANOVA with terms for sequence, subjects within sequence, period, treatment and the baseline INR value
SecondaryWarfarin: Peak International Normalised Ratio Adjusted to Baseline (INRmax,Base)

Peak international normalised ratio for warfarin adjusted for baseline value (before any trial drug administration) of peak international normalised ratio

Time frame:
0 hours (h), 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · Ratio
Warfarin: Peak International Normalised Ratio Adjusted to Baseline (INRmax,Base)
RatioWarfarinEmpa Plus Warfarin
Warfarin: Peak International Normalised Ratio Adjusted to Baseline (INRmax,Base)0.69 ± NA0.69 ± 46.12
Statistical analysis
  • Warfarin vs Empa Plus Warfarin · ANOVA · Geometric mean ratio: 0.99 · 95% CI 0.67 to 1.48Based on ANOVA with terms for sequence, subjects within sequence, period, treatment and the baseline INR value
SecondaryWarfarin: Peak Prothrombin Time (PTmax)

Peak prothrombin time

Time frame:
0 hours (h), 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · s
Warfarin: Peak Prothrombin Time (PTmax)
sWarfarinEmpa Plus Warfarin
Warfarin: Peak Prothrombin Time (PTmax)20.17 ± NA18.07 ± 17.34
Statistical analysis
  • Warfarin vs Empa Plus Warfarin · ANOVA · Geometric mean ratio: 0.90 · 95% CI 0.79 to 1.02Based on ANOVA with terms for sequence, subjects within sequence, period, treatment and the baseline PT value
SecondaryWarfarin: Area Under the INR-time Curve From 0 to Last Measurable Data Point Adjusted to Baseline (INR AUEC0-tz,Base)

Area under the INR-time curve from time of dosing to time of last measurable data point adjusted for baseline value (before any trial drug administration) of area under the INR-time curve

Time frame:
0 hours (h), 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · ratio*h
Warfarin: Area Under the INR-time Curve From 0 to Last Measurable Data Point Adjusted to Baseline (INR AUEC0-tz,Base)
ratio*hWarfarinEmpa Plus Warfarin
Warfarin: Area Under the INR-time Curve From 0 to Last Measurable Data Point Adjusted to Baseline (INR AUEC0-tz,Base)32.42 ± NA36.30 ± 55.85
Statistical analysis
  • Warfarin vs Empa Plus Warfarin · ANOVA · Geometric mean ratio: 1.12 · 95% CI 0.64 to 1.95Based on ANOVA with terms for sequence, subjects within sequence, period, treatment and the baseline PT value
SecondaryWarfarin: Area Under the PT-time Curve From 0 to Last Measurable Data Point (PT AUEC0-tz)

Area under the PT-time curve from time of dosing to time of last measurable data point

Time frame:
0 hours (h), 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · s*hr
Warfarin: Area Under the PT-time Curve From 0 to Last Measurable Data Point (PT AUEC0-tz)
s*hrWarfarinEmpa Plus Warfarin
Warfarin: Area Under the PT-time Curve From 0 to Last Measurable Data Point (PT AUEC0-tz)2508.34 ± NA2281.54 ± 7.61
Statistical analysis
  • Warfarin vs Empa Plus Warfarin · ANOVA · Geometric mean ratio: 0.91 · 95% CI 0.84 to 0.98Based on ANOVA with terms for sequence, subjects within sequence, period, treatment and the baseline PT value
SecondaryWarfarin: Peak Prothrombin Time Adjusted to Baseline (PTmax,Base)

Peak prothrombin time adjusted for baseline value (before any trial drug administration) of peak prothrombin

Time frame:
0 hours (h), 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · s
Warfarin: Peak Prothrombin Time Adjusted to Baseline (PTmax,Base)
sWarfarinEmpa Plus Warfarin
Warfarin: Peak Prothrombin Time Adjusted to Baseline (PTmax,Base)6.69 ± NA6.51 ± 41.50
Statistical analysis
  • Warfarin vs Empa Plus Warfarin · ANOVA · Geometric mean ratio: 0.97 · 95% CI 0.68 to 1.40Based on ANOVA with terms for sequence, subjects within sequence, period, treatment and the baseline PT value
SecondaryWarfarin: Area Under the PT-time Curve From 0 to Last Measurable Data Point Adjusted to Baseline (PT AUEC0-tz,Base)

Area under the PT-time curve from time of dosing to time of last measurable data point adjusted for baseline value (before any trial drug administration) of area under the PT-time curve

Time frame:
0 hours (h), 1h, 2h, 4h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 144h, 168h after administration of warfarin for both warfarin alone and warfarin plus empagliflozin
Reported as:
Geometric mean · s*hr
Warfarin: Area Under the PT-time Curve From 0 to Last Measurable Data Point Adjusted to Baseline (PT AUEC0-tz,Base)
s*hrWarfarinEmpa Plus Warfarin
Warfarin: Area Under the PT-time Curve From 0 to Last Measurable Data Point Adjusted to Baseline (PT AUEC0-tz,Base)419.24 ± NA354.97 ± 54.49
Statistical analysis
  • Warfarin vs Empa Plus Warfarin · ANOVA · Geometric mean ratio: 0.85 · 95% CI 0.47 to 1.51Based on ANOVA with terms for sequence, subjects within sequence, period, treatment and the baseline PT value
SecondaryClinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by Investigator

Clinically relevant abnormalities for physical examination, vital signs, ECG, blood chemistry and assessment of tolerability by investigator. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.

Time frame:
Drug administration until beginning of next sequence/end of trial, 35 days
Reported as:
Number · participants
Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by Investigator
participantsEmpaWarfarinEmpa Plus Warfarin
Clinically Relevant Abnormalities for Physical Examination, Vital Signs, ECG, Blood Chemistry and Assessment of Tolerability by Investigator000

Adverse events

Collected over Drug administration until beginning of next sequence/end of trial, 35 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Empa—0/18 (0%)4/18 (22.2%)
Warfarin—0/18 (0%)5/18 (27.8%)
Empa Plus Warfarin—0/18 (0%)2/18 (11.1%)
Most frequent other events
Most frequent other events
EventEmpaWarfarinEmpa Plus Warfarin
HeadacheNervous system disorders3/182/180/18
VomitingGastrointestinal disorders0/181/180/18
IndurationGeneral disorders0/180/181/18
Arthropod stingInjury, poisoning and procedural complications0/180/181/18
Muscle spasmsMusculoskeletal and connective tissue disorders0/181/180/18
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/180/180/18
PetechiaeSkin and subcutaneous tissue disorders0/181/180/18

Baseline characteristics

Age, Continuous
Age, Continuous(years)Study Overall
Mean34.8 ± 7.0
Sex: Female, Male
Sex: Female, Male(Participants)Study Overall
Female0
Male18
08

Study locations

1 site
  • 1245.18.1 Boehringer Ingelheim Investigational Site
    Biberach, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010 and a primary completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2010
First posted
Apr 27, 2010
Start
May 2010
Primary completionActual
Jul 2010
Results first posted
Jul 23, 2014
Last update
Jul 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01111331
Responsible party
Sponsor
First posted
Apr 27, 2010
Start date
May 2010
Primary completion
Jul 2010
Results posted
Jul 23, 2014
Last update
Jul 23, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Warfarin

Start the discussion